跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN11052603
ISRCTN11052603已完成1 期

Phase I trial: MM-120-101

Mind Medicine Inc0 个研究点目标入组 30 人开始时间: 2024年5月21日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
30
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ot Specified

入排标准

性别
All

入选标准

  • •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

排除标准

  • •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

研究者

相似试验

进行中（未招募）
1 期
Phase I trial MM-120-102Healthy volunteers
ISRCTN15997848Mind Medicine Inc.32
进行中（未招募）
1 期
Phase I trial MM-402-101Healthy volunteers
ISRCTN13877948Mind Medicine Inc.40
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended
ISRCTN15751828Omeros Corporation (United States)12
进行中（未招募）
1 期
A study to find and investigate a safe dose of BI 836858 in combination with decitabine for patients with acute myeloid leukemia (AML)patients with acute myeloid leukemiaMedDRA version: 19.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864
EUCTR2015-002892-30-ESBoehringer Ingelheim España, S.A.200
进行中（未招募）
1 期
A study to find and investigate a safe dose of BI 836858 in combination with decitabine for patients with acute myeloid leukemia (AML)patients with acute myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864
EUCTR2015-002892-30-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.200